News | February 03, 2024
Abbott India posts Q3 FY24 PAT at Rs. 310.98 Cr
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Subscribe To Our Newsletter & Stay Updated
